Cancer News and Research

Latest Cancer News and Research

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Results from the international phase III SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

In pooled prospective data from 977,282 UK adults, preferring tea or coffee “very hot” was associated with more than threefold higher risk of esophageal squamous cell carcinoma compared with preferring drinks “warm,” while drink temperature showed no material association with adenocarcinoma risk. Consuming six or more hot drinks daily was independently associated with higher squamous cell carcinoma risk, and modeling estimated that about 440 UK cases each year could be prevented by switching from “very hot” to “hot” drinks if the association is causal.

14 Sep 2026

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

14 Sep 2026

Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

A laboratory study tested how ultra-processed, unprocessed, and mixed diets affected survival in 127 lobster cockroaches, Nauphoeta cinerea. Cockroaches fed only ultra-processed foods had higher mortality than those given unprocessed or mixed diets, although the study could not determine whether processing, ingredients, nutrition, or differences in food intake caused the effect.

13 Sep 2026

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1b DeLLphi-308 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

Obesity suppresses natural protection against breast cancer growth

A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason why obesity is a risk factor for breast cancer.

11 Sep 2026

Cancer News and Research

Latest Cancer News and Research

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

MRI surveillance alone improves outcomes for patients with small-cell lung cancer

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

More data, more answers? A 1.9 million-person health study shows why scale has limits

Cockroaches have a reputation for surviving almost anything, but this diet proved deadly

Subcutaneous tarlatamab exhibits low toxicity rates in phase 1b trial

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

MD Anderson trial challenges local consolidative therapy paradigm in NSCLC

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Low discontinuation rates confirm manageable safety of iza-bren

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Obesity suppresses natural protection against breast cancer growth

Understanding the DNA Damage Response in Innate Immunity eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Newsletters you may be interested in